



Enlitic, Inc.
1635 Foxtrail Drive, Suite 111A
Loveland, CO 80538

12 May 2026

Enlight go-live at New Zealand's largest private radiology provider, validating Intelrad integration

- **Enlight go-live at RHCNZ Medical Imaging Group, New Zealand's largest private radiology provider, with 65+ clinics and 170+ specialist radiologists**
- **First production deployment of Enlitic's integration with Intelrad IntelePACS, one of 8 global OEMs actively engaged with Enlitic's Migrations and Data Management offering**
- **Initial deployment of Enlightenment focused on hanging protocols, standardising imaging study presentation across RHCNZ's nationwide network**
- **RHCNZ has identified additional Enlightenment use cases for potential future rollout**
- **Follows record Q1 FY26 contract wins of A\$5.1m in total contract value, including US\$2.95m with Penn Medicine, St. Jude Children's Research Hospital and Parkland Health**

Enlitic, Inc. (ASX: ENL) ("Enlitic" or the "Company") is pleased to advise that its Enlightenment platform has gone live at RHCNZ Medical Imaging Group ("RHCNZ"), New Zealand's largest private radiology provider. The deployment represents Enlitic's first customer in New Zealand and the first production use of its integration with Intelrad's IntelePACS.

RHCNZ operates 65+ clinics nationwide under the Auckland Radiology, Bay Radiology and Pacific Radiology brands, with more than 1,400 staff and 170+ specialist radiologists. The group delivers more than 35% of radiology services across New Zealand, making it the country's largest private radiology provider.

RHCNZ's initial deployment of Enlightenment focuses on hanging protocols, standardising how imaging studies are presented to radiologists at the point of read. By implementing consistent display logic across its network, Enlightenment is expected to improve reading efficiency and diagnostic consistency. RHCNZ has identified additional Enlightenment use cases for potential future rollout beyond this initial phase.

The go-live also represents the first production deployment of Enlitic's integration with Intelrad's IntelePACS, a leading PACS platform. Developed over the past year the integration enables Enlightenment to be deployed directly into Intelrad-hosted environments. Intelrad is one of 8 global OEMs now actively engaged with Enlitic's Migrations and Data Management offering, and validation in a live enterprise environment strengthens Enlitic's position within the Intelrad channel.

The RHCNZ go-live follows a record Q1 FY26, in which Enlitic signed A\$5.1m in total contract value across 17 agreements, including US\$2.95m with Penn Medicine (ASX: 23 March 2026), St. Jude Children’s Research Hospital (ASX: 31 March 2026) and Parkland Health (ASX: 1 April 2026). The RHCNZ deployment reflects the Company’s broader strategy of expanding its Ensign installed base across enterprise environments through both direct relationships and OEM channels.

Enlitic CEO Michael Sistenich said: *“This go-live validates both the Ensign platform and our Intelrad integration in a live production environment, at one of the largest private radiology networks in the Southern Hemisphere. RHCNZ is exactly the kind of partner we want to be growing with as we expand into new markets.*

Hanging protocols represent the starting point of the integration of the Ensign platform. RHCNZ has a pipeline of potential further Ensign use cases it wants to unlock and we see this as a long-term relationship. A deployment at a network of this scale also gives us a strong reference point in the Intelrad channel, and as Ensign embeds across RHCNZ’s workflows, the pathway to recurring SaiS revenue becomes increasingly clear.”

RHCNZ Chief Digital Office Shayne Hunter said: *“This is a significant step forward in our commitment to delivering smarter, more efficient radiology workflows, Ensign enables us to streamline how studies are presented to our radiologists, supporting greater consistency and efficiency across our network. Hanging Protocols is just the beginning with several other opportunities in the pipeline.”*

ENDS

This announcement was authorised for release by the Board of Enlitic, Inc.

Enquiries

Enlitic Investor Relations

Australia:

invest_au@enlitic.com

Six Degrees Investor Relations

Henry Jordan

Henry.jordan@sdir.com.au

+61 431 271 538

About Enlitic

Enlitic is a software company that uses artificial intelligence to develop software products that manage medical imaging data in radiology (such as MRI, CT scans, Xray and ultrasound images) and licences such products to healthcare providers. Enlitic’s products (including its current product offering and product suite under development) seek to standardise, protect, integrate, and analyse data to create the foundation of a real-world evidence platform that can improve clinical workflows, increase efficiencies, and expand capacity. Read more at enlitic.com.

Enlitic’s CDIs are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933 as amended, and in accordance with the procedures established pursuant to the

provisions of a no action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this announcement.

Forward-looking statements

Certain statements made during or in connection with this announcement contain or comprise certain forward-looking statements regarding the Company, its projected cash flow, financial performance, its customer contracts and customer pipeline and product development. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such expectations are only predictions and are subject to inherent risks and uncertainties which could cause actual values, results, performance or achievements to differ materially from those expressed, implied or projected in any forward looking statements and no assurance can be given that such expectations will prove to have been correct.

Accordingly, results could differ materially from those set out in the forward-looking statements as a result of, among other factors, changes in economic and market conditions, delays or changes in product development and realisation of customer pipeline, changes in demand, success of business and operating initiatives, changes in the regulatory environment and other government actions, fluctuations in exchange rates and business and operational risk management.

To the maximum extent permitted by law, each of the Company, its officers, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the material contained in these forward-looking statements and excludes all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in forward-looking statements or any error or omission. The Company undertakes no obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events other than required by the applicable laws, including the ASX Listing Rules. Accordingly, you should not place undue reliance on any forward-looking statement.